APLT Stock Price, Applied Therapeutics Inc Quote, Chart

Market Summary

USD4.27-0.04

Delayedas of 25 Apr 2024, 10:13 am

-0.93%

APLT Alerts

4 major insider sales recently.

APLT Stock Price

View Fullscreen

APLT RSI Chart

APLT Valuation

Market Cap

456.4M

Price/Earnings (Trailing)

-3.81

Price/Sales (Trailing)

45.67

Price/Free Cashflow

-8.27

APLT Price/Sales (Trailing)

APLT Profitability

Return on Equity

698.49%

Return on Assets

-218.41%

Free Cashflow Yield

-12.09%

APLT Fundamentals

APLT Revenue

Revenue (TTM)

10.0M

APLT Earnings

Earnings (TTM)

-119.8M

Earnings Growth (Yr)

-161.13%

Earnings Growth (Qtr)

11.07%

Breaking Down APLT Revenue

52 Week Range

4.36

(Low)(High)

Last 7 days

-11.0%

Last 30 days

-36.3%

Last 90 days

47.3%

Trailing 12 Months

220.9%

How does APLT drawdown profile look like?

APLT Financial Health

Current Ratio

0.76

APLT Investor Care

Shares Dilution (1Y)

60.70%

Diluted EPS (TTM)

-1.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	10.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Applied Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	hooks corwin dale	acquired	-	-	300,000	chief commercial officer
Mar 14, 2024	shendelman shoshana	sold	-1,717,110	5.39	-318,573	president and ceo
Mar 14, 2024	perfetti riccardo	sold	-597,234	5.39	-110,804	chief medical officer
Mar 14, 2024	funtleyder leslie d.	sold	-154,839	5.39	-28,727	chief financial officer
Mar 14, 2024	hansard adam	sold	-263,415	5.39	-48,871	chief commercial officer
Dec 28, 2023	chinoporos constantine	acquired	-	-	300,000	see remarks
Dec 21, 2023	hansard adam	acquired	-	-	400,000	chief commercial officer
Dec 21, 2023	perfetti riccardo	acquired	-	-	450,000	chief medical officer
Dec 21, 2023	shendelman shoshana	acquired	-	-	1,540,000	president and ceo
Dec 01, 2023	kanter stacy j.	bought	65,367	2.1789	30,000	-

Which funds bought or sold APLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Relyea Zuckerberg Hanson LLC	unchanged	-	138,000	272,000	0.05%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	72,474	72,474	-%
Apr 19, 2024	Cutler Group LLC / CA	new	-	4,000	4,000	-%
Apr 19, 2024	DENALI ADVISORS LLC	new	-	228,480	228,480	0.07%
Mar 11, 2024	VANGUARD GROUP INC	added	126	7,264,760	10,822,100	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	112,238	112,238	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	new	-	13,668,800	13,668,800	0.30%
Feb 15, 2024	JANE STREET GROUP, LLC	reduced	-35.08	-64,031	441,885	-%
Feb 14, 2024	Propel Bio Management, LLC	new	-	18,006,200	18,006,200	14.93%
Feb 14, 2024	VR Adviser, LLC	added	10.46	6,849,000	20,937,500	1.44%

Are Funds Buying or Selling APLT?

Are funds buying APLT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APLT

No. of Funds

APLT Alerts

4 major insider sales recently.

Unveiling Applied Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	janus henderson group plc	6.1%	6,414,642	SC 13G
Mar 05, 2024	shendelman shoshana	8.2%	8,646,891	SC 13D/A
Feb 22, 2024	propel bio management, llc	10.5%	8,071,526	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	7,877,817	SC 13G/A
Feb 14, 2024	armistice capital, llc	0%	0	SC 13G/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	7,715,197	SC 13G/A
Feb 14, 2024	perceptive advisors llc	5.9%	4,580,249	SC 13G/A
Feb 14, 2024	orbimed advisors llc	0.0%	0	SC 13G/A
Feb 14, 2024	alexandria real estate equities, inc.	15.4%	12,859,054	SC 13G/A
Feb 13, 2024	vestal point capital, lp	5.4%	4,155,000	SC 13G

Recent SEC filings of Applied Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 15, 2024	3	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	8-K	Current Report
Apr 11, 2024	PRE 14A	PRE 14A
Mar 29, 2024	8-K	Current Report
Mar 22, 2024	S-3	S-3
Mar 18, 2024	3	Insider Trading

Peers (Alternatives to Applied Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Applied Therapeutics Inc News

Latest updates

Applied Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	-	-	-	-	10,660
Operating Expenses	31.3%	20,340	15,495	17,176	21,518
S&GA Expenses	7.0%	5,038	4,710	5,293	5,583
R&D Expenses	41.9%	15,303	10,785	11,883	15,935
Net Income	11.1%	-37,679	-42,370	-29,577	-10,137
Net Income Margin	-Infinity%	-11.98*	-	-	-
Free Cashflow	-15.5%	-17,005	-14,726	-16,452	-6,990

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	21.3%	55.00	45.00	44.00	30.00	38.00	57.00	78.00	65.00	90.00	119	137	156	105	125	151	166	48.00	37.00	47.00	17.00	20.00
Current Assets	22.2%	54.00	44.00	43.00	29.00	37.00	56.00	77.00	64.00	88.00	117	135	154	103	123	149	164	46.00	37.00	47.00	17.00	20.00
Cash Equivalents	33.2%	50.00	37.00	36.00	23.00	17.00	40.00	56.00	38.00	54.00	70.00	78.00	84.00	57.00	49.00	101	93.00	19.00	13.00	41.00	15.00	19.00
Liabilities	28.0%	72.00	56.00	48.00	34.00	34.00	47.00	52.00	23.00	27.00	32.00	25.00	21.00	23.00	22.00	20.00	10.00	16.00	7.00	7.00	6.00	4.00
Current Liabilities	28.2%	71.00	56.00	47.00	33.00	33.00	47.00	52.00	22.00	26.00	31.00	23.00	20.00	21.00	21.00	19.00	8.00	14.00	7.00	7.00	6.00	4.00
Shareholder's Equity	-Infinity%	-17.15	-	-	-	4.00	10.00	26.00	42.00	63.00	87.00	112	135	82.00	103	130	156	33.00	31.00	40.00	-	-
Retained Earnings	-8.7%	-468	-430	-388	-358	-348	-334	-315	-289	-266	-239	-210	-184	-160	-137	-107	-79.14	-66.77	-49.14	-38.42	-29.99	-21.26
Additional Paid-In Capital	7.5%	451	420	384	355	353	344	341	331	329	326	323	320	243	240	237	235	99.00	80.00	78.00	2.00	2.00
Shares Outstanding	10.0%	85.00	77.00	62.00	48.00	48.00	34.00	27.00	26.00	26.00	25.00	26.00	24.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	64.00	-	-	-	28.00	-	-	-	393	-	-	-	659	-	-	-	68.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-15.5%	-17,005	-14,726	-16,452	-6,990	-15,893	-19,390	-18,400	-24,410	-26,942	-15,665	-25,908	-22,213	-22,750	-20,693	-15,911	-18,855	-12,407	-7,839	-9,059	-7,002	-5,869
Share Based Compensation	-11.4%	1,626	1,836	1,843	2,055	1,998	3,297	2,231	2,077	2,849	2,645	2,702	2,981	2,555	2,403	1,737	1,331	1,348	1,219	3,279	325	92.00
Cashflow From Investing	-	-	-	-	13,872	-6,905	5,021	5,529	9,525	11,807	8,518	16,780	-24,672	28,444	-30,246	24,044	-41,711	-	-	-	-	-
Cashflow From Financing	77.7%	29,446	16,567	29,151	-622	-933	-971	30,385	-789	-1,184	-1,080	3,495	73,486	3,093	-1,236	218	134,219	18,320	-294	35,449	2,940	21,056

APLT Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
REVENUE:
Total Revenue	$ 9,993
COSTS AND EXPENSES:
Research and development	53,905	$ 55,634
General and administrative	20,623	27,316
Total costs and expenses	74,528	82,950
LOSS FROM OPERATIONS	(64,535)	(82,950)
OTHER INCOME (EXPENSE), NET:
Interest income	1,372	685
Change in fair value of warrant liabilities	(56,573)	(66)
Other expense	(27)	(177)
Total other income (expense), net	(55,228)	442
Net loss	$ (119,763)	$ (82,508)
Net loss per share attributable to common stockholders-basic (in dollars per share)	$ (1.42)	$ (2.18)
Net loss per share attributable to common stockholders-diluted (in dollars per share)	$ (1.42)	$ (2.18)
Weighted-average common stock outstanding-basic (in shares)	84,244,494	37,825,431
Weighted-average common stock outstanding-diluted (in shares)	84,244,494	37,825,431
License
REVENUE:
Total Revenue	$ 9,219
Research and development services
REVENUE:
Total Revenue	$ 774

APLT Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 49,898	$ 16,657
Investments		13,923
Current portion of security deposits and leasehold improvements	254	57
Prepaid expenses and other current assets	4,234	6,671
Total current assets	54,386	37,308
Noncurrent portion of security deposits and leasehold improvements		198
Operating lease right-of-use asset	447	857
TOTAL ASSETS	54,833	38,363
CURRENT LIABILITIES:
Current portion of operating lease liabilities	429	477
Accounts payable	1,742	4,534
Accrued expenses and other current liabilities	15,286	14,756
Warrant liabilities	53,725	13,657
Total current liabilities	71,182	33,424
NONCURRENT LIABILITIES:
Noncurrent portion of operating lease liabilities	38	414
Clinical holdback - long-term portion	759	464
Total noncurrent liabilities	797	878
Total liabilities	71,979	34,302
STOCKHOLDERS' (DEFICIT)/EQUITY:
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 84,869,832 shares issued and outstanding as of December 31, 2023 and 48,063,358 shares issued and outstanding as of December 31, 2022	8	5
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022
Additional paid-in capital	451,432	352,828
Accumulated other comprehensive income		51
Accumulated deficit	(468,586)	(348,823)
Total stockholders' (deficit)/equity	(17,146)	4,061
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY	$ 54,833	$ 38,363

About Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

CEO	Dr. Shoshana Shendelman Ph.D.
WEBSITE	appliedtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Applied Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Applied Therapeutics Inc? What does APLT stand for in stocks?

APLT is the stock ticker symbol of Applied Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Therapeutics Inc (APLT)?

As of Wed Apr 24 2024, market cap of Applied Therapeutics Inc is 456.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers. The fair value of Applied Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APLT is over valued or under valued. Whether Applied Therapeutics Inc is cheap or expensive depends on the assumptions which impact Applied Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLT.

What is Applied Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, APLT's PE ratio (Price to Earnings) is -3.81 and Price to Sales (PS) ratio is 45.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLT PE ratio will change depending on the future growth rate expectations of investors.